Boston Scientific has launched a U.S. trial of two next-generation leads for defibrillators and pacemakers, working toward FDA approval after completing the first implant.
Boston Scientific won FDA approval for a new crop of implantable defibrillators and heart failure devices, helping the company move forward with sales and development of its cardiac rhythm management system.
Boston Scientific is ramping up neuromodulation efforts with a new clinical trial of its implantable deep brain stimulation device for patients with Parkinson's disease.
As part of its strategy to sell more products in foreign markets, Boston Scientific announced the signing of a distribution partnership agreement allowing Israel's Amos Gazit Ltd to market and sell its interventional cardiology, peripheral interventions, endoscopy and urology/women's health products.
Boston Scientific has launched its much-hyped S-ICD in Asia, notching the first implant of the under-the-skin system in Hong Kong as it looks to expand the market for the device.
It's a crowded market for transcatheter aortic devices, and Boston Scientific is trying to get a leg up on the competition. The company is celebrating positive study results for its transcatheter aortic valve replacement, touting data that it hopes will set it apart from its market rivals.
Axonics Modulation Technologies got itself a $32.6 million Series A funding round that will help advance its implantable neuromodulation technology into human clinical studies to treat a variety of conditions.
In 2013, a number of outside forces hammered the med tech industry. While things could have been better, most of the top 10 companies in the sector still enjoyed moderate year-over-year revenue gains.
Boston Scientific gained a CE mark for a new platinum bare metal stent to treat coronary artery disease.
Forget organic growth. In 2013, some of the biggest moves into new or expanded markets in the med tech world came through serious M&A activity. The top deals announced or closed in 2013 created...